Devil's Claw and arthritis

What 2 graded rows on devil's claw agree on for arthritis, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Devil's Claw page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Devil's Claw page, with its PubMed record.

Supplement

Devil's Claw Choose another

2 rows · 182 people

Split. 1 row found an improvement and 1 had mixed results.

Mixed

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside. Outlined: mixed results.

From the rows

The best-graded row, grade D, is a randomized trial of 122 people (2000) and found an improvement.

The rows run from 60 to 122 people, published from 2000 to 2021: 2 single studies.

1 improved · 1 mixed

Grade DHip and knee osteoarthritis pain and function versus diacerhein · Improved
RCT · n 122 · 2000 · Adults with knee and/or hip osteoarthritis (France)
2,610 mg/day (6 capsules) · 4 months
Pain, function and Lequesne scores improved similarly with devil's claw and diacerhein 100 mg/day; the devil's claw group used less diclofenac and paracetamol-caffeine rescue and had fewer adverse events.
Row on the Devil's Claw page · PubMed 11143915 (opens PubMed)
Grade DKnee osteoarthritis pain and function versus meloxicam · Mixed
RCT · n 60 · 2021 · Adults aged 40–60 with mild knee osteoarthritis (Kellgren-Lawrence grade 1–2, Iran)
960 mg/day (2 × 480 mg) · 1 month (meloxicam 15 mg/day for 10 days), follow-up to 8 weeks
Pain (VAS), WOMAC and Oxford Knee scores improved in both groups over time with no significant difference between devil's claw and meloxicam.
Row on the Devil's Claw page · PubMed 34712343 (opens PubMed)